
|Slideshows|March 2, 2016
Neuro News Roundup: Multiple Sclerosis
Author(s)Mark L. Fuerst
Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.
Advertisement
New recommendations aim to reduce the risk for progressive multifocal leukoencephalopathy (PML) with use of natalizumab in patients with relapsing remitting multiple sclerosis (RRMS). RRMS patients taking natalizumab who seroconvert to high levels of signaling antibodies are at increased risk of PML. In a new finding, seven loci have been added to the list of genuine MS genetic risk factors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA PDUFA Watch: Neurology Decisions to Track Through Late September
2
Favorable Phase 1 Data for Orexin-2 Agonist BP-205, Broader Pipeline Progress Headline Harmony's Q2 Update
3
FDA Clears VoxNeuro's EEG-Based Cognitive Assessment Software
4
Exploring Neprilysin and Amyloid-Beta–Tau Axes in Alzheimer Disease
5

















